The efficacy and the safety of gemcitabine / S-1 combination therapy in patients with advanced non-resectable or post-operative recurrent biliary tract cancer -multicenter phase II study

Trial Profile

The efficacy and the safety of gemcitabine / S-1 combination therapy in patients with advanced non-resectable or post-operative recurrent biliary tract cancer -multicenter phase II study

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2010

At a glance

  • Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Biliary cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Jan 2010 Status changed from recruiting to completed as reported by University Hospital Medical Information Network Japan record.
    • 07 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top